This physician survey is part of an
overall evaluation of the Centers for Medicare and Medicaid
Services (CMS)'s congressionally mandated Competitive Acquisition
for Part B Drugs Program (CAP). MMA section 303(d) requires the
implementation of the CAP for those drugs and biologicals covered
by Medicare Part B that are not paid on a cost or prospective
payment system. Since summer 2006 (the original date of January 1,
2006 was delayed), physicians have been given a choice between (1)
buying and billing for these covered drugs under the average sales
price (ASP) system mandated in section 303(c) of the MMA; or (2)
obtaining these drugs from vendors selected for the CAP in a
competitive bidding process. If the physician elects to obtain
drugs from a CAP vendor, the vendor will bill Medicare for the drug
(the physician will continue to bill Medicare for any drug
administration fees). The CAP is therefore a major change in the
way Part B-covered drugs and biologicals are acquired and
reimbursed for, requiring CMS to consider many design options. The
CAP mandate includes a Report to Congress, which will include
results from this physician survey.
PL:
Pub.L. 108 - 173 1 Name of Law: Medicare Prescription Drug,
Improvement, and Modernization Act of 2003
A one-time increase in provider
burden of 296.5 hours is necessary to field a survey of physicians
to assess physician satisfaction with the Competitive Acquisition
Program for Pat B Drugs and Biologicals. Section 303(d)(2) of the
Medicare Prescription Drug, Improvement, and Modernization Act of
2003 (Pub. L. 108-173) requires the Secretary of the Department of
Health and Human Services to submit a Report to Congress by July 1,
2008 that includes information on physician satisfaction with this
program. A survey is the only feasible method of systematically
collecting this information. The survey is limited to only
questions that address satisfaction, including reasons for
participating, as well as information about participating and
non-participating physicians that may permit comparisons between
those who elected to participate and those who did not. The burden
to individual physicians is small for physicians participating in
the program (15 minutes in total) and minimal for those not
participating (eight minutes in total). There are no capital,
startup, operation, or maintenance costs to respondents.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.
CMS-10223 CAP_OMB_package_revised(3) 12_12_07.doc
Medicare Competitive Acquisition Program (CAP) for Part B Drugs Evaluation: CAP Physician Survey (CMS-10223)